HY-0102 + gemcitabine + nab-paclitaxel

HY-0102 + gemcitabine + nab-paclitaxel is an investigational combination therapy primarily studied for the treatment of advanced or metastatic solid tumors, particularly pancreatic cancer. HY-0102 is a novel antibody drug (cellular or molecular target and precise nature undisclosed in public sources), actively investigated as monotherapy and in combination regimens. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while nab-paclitaxel is an albumin-bound formulation of the microtubule stabilizer paclitaxel, improving drug delivery to tumors. This combination exploits complementary antineoplastic mechanisms: HY-0102 potentially augments immune or direct antitumor effects, gemcitabine impairs tumor proliferation, and nab-paclitaxel disrupts microtubule function, leading to synergistic antitumor activity. The current development focuses on patients with metastatic or locally advanced pancreatic cancer, among other possible solid tumor indications[1][3][5][7].

Other names

AG regimen (for gemcitabine + nab-paclitaxel in some contexts)